Bronchial and Peripheral Murine Lung Carcinomas Induced by T790M-L858R Mutant EGFR Respond to HKI-272 and Rapamycin Combination Therapy

Danan Li, Takeshi Shimamura, Hongbin Ji, Liang Chen, Henry J. Haringsma, Kate McNamara, Mei-Chih Liang, Samanthi A. Perera, Sara Zaghlul, Christa L. Borgman, Shigeto Kubo, Masaya Takahashi, Yanping Sun, Lucian R. Chirieac, Robert F. Padera, Neal I. Lindeman, Pasi A. Jänne, Roman K. Thomas, Matthew L. Meyerson, Michael J. EckJeffrey A. Engelman, Geoffrey I. Shapiro*, Kwok Kin Wong

*此作品的通信作者

研究成果: Article同行評審

201 引文 斯高帕斯(Scopus)

摘要

The EGFR T790M mutation has been identified in tumors from lung cancer patients that eventually develop resistance to erlotinib. In this study, we generated a mouse model with doxycycline-inducible expression of a mutant EGFR containing both L858R, an erlotinib-sensitizing mutation, and the T790M resistance mutation (EGFR TL). Expression of EGFR TL led to development of peripheral adenocarcinomas with bronchioloalveolar features in alveoli as well as papillary adenocarcinomas in bronchioles. Treatment with an irreversible EGFR tyrosine kinase inhibitor (TKI), HKI-272, shrunk only peripheral tumors but not bronchial tumors. However, the combination of HKI-272 and rapamycin resulted in significant regression of both types of lung tumors. This combination therapy may potentially benefit lung cancer patients with the EGFR T790M mutation.

原文English
頁(從 - 到)81-93
頁數13
期刊Cancer Cell
12
發行號1
DOIs
出版狀態Published - 10 7月 2007

指紋

深入研究「Bronchial and Peripheral Murine Lung Carcinomas Induced by T790M-L858R Mutant EGFR Respond to HKI-272 and Rapamycin Combination Therapy」主題。共同形成了獨特的指紋。

引用此